Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Reach OutAccesswire • 02/27/25
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate UpdateBusiness Wire • 02/26/25
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Reach OutAccesswire • 02/26/25
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to ConnectAccesswire • 02/25/25
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference CallBusiness Wire • 02/12/25
All You Need to Know About Corcept (CORT) Rating Upgrade to Strong BuyZacks Investment Research • 01/29/25
Buy These 5 Stocks With Recent Price Strength Amid a Volatile JanuaryZacks Investment Research • 01/29/25
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 01/24/25
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With HypercortisolismBusiness Wire • 12/30/24
Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with HypercortisolismBusiness Wire • 12/16/24
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control DiabetesBusiness Wire • 12/12/24
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder StudyZacks Investment Research • 12/12/24
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)Business Wire • 12/11/24
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum StockZacks Investment Research • 12/11/24